Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Myelodysplastic Syndromes 7Lymphoma, Follicular 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Prolymphocytic 4Leukemia 4Burkitt Lymphoma 4Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Primary Myelofibrosis 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Congenital Abnormalities 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

fludarabine 6Cyclophosphamide 6fludarabine phosphate 5Whole-Body Irradiation 5Mycophenolic Acid 4Tacrolimus 2Sirolimus 2Antilymphocyte Serum 2Allopurinol 2itacitinib 1Peripheral Blood Stem Cell Transplantation 1Hematopoietic Stem Cell Transplantation 1Cyclosporine 1Association 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × Allopurinol × Myeloid × Clear all
NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hematologic Diseases, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡